Long-term outcomes of the micronet-covered stent system routine use for carotid revsacularization in stroke prevention: PARADIGM-Extend 5 year evidence

Abstract Background Diffusion-weighted magnetic resonance imaging indicates that micronet-covered embolic prevention stent system effectively minimizes peri-procedural and prevents lesion-related post-procedural cerebral embolism in carotid artery stenting but long-term clinical evidence is missing....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2020-11, Vol.41 (Supplement_2)
Hauptverfasser: Mazurek, A, Borratynska, A, Tomaszewski, T, Lesniak-Sobelga, A, Wilkolek, P, Gancarczyk, U, Brozda, M, Sobieraj, E, Sikorska, M, Czyz, L, Urbanczyk, M, Trystula, M, Drazkiewicz, T, Podolec, P, Musialek, P
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_2
container_start_page
container_title European heart journal
container_volume 41
creator Mazurek, A
Borratynska, A
Tomaszewski, T
Lesniak-Sobelga, A
Wilkolek, P
Gancarczyk, U
Brozda, M
Sobieraj, E
Sikorska, M
Czyz, L
Urbanczyk, M
Trystula, M
Drazkiewicz, T
Podolec, P
Musialek, P
description Abstract Background Diffusion-weighted magnetic resonance imaging indicates that micronet-covered embolic prevention stent system effectively minimizes peri-procedural and prevents lesion-related post-procedural cerebral embolism in carotid artery stenting but long-term clinical evidence is missing. Purpose To provide long-term clinical and duplex ultrasound evaluation of safety and efficacy of the system use in consecutive carotid revascularization patients. Methods PARADIGM-EXTEND is in all-comer, all-referrals-tracked study with no exclusion criteria other than lack of NeuroVascular Team-determined indication. Clinically asymptomatic patients receive revascularization only in case of increased-stroke-risk characteristics. Adverse events are independently adjudicated. Results Currently 451 patients (48–87 years, 59% symptomatic, 127 women) with 490 arteries crossed the first follow-up window of 30 days. There has been 100% micronet-covered embolic prevention stent system use (ie, no other stent type/s used throughout study). Proximal/distal intra-procedural neuroprotection use was 38.3%/61.7%. Large balloon/high-pressure stent optimization was routine, leading to a single-digit (mean 6.9%) residual diameter stenosis. Independent neurologist and duplex evaluation are before and after revascularization (48h and 30 days, then yearly). Peri-procedural death or major ischemic stroke rate was 0%. One event (prior infarct scar asymptomatic extension in prolonged hypotension course) was adjudicated as minor stroke (0.22%), and there was 1 periprocedural MI (type 2, in 2-vessel non-revascularizable CTO; 0.22%). By 30 days there were no further ischaemic strokes (0%) but there was 1 haemorrhagic transformation that led to death (0.22%) and 1 bleeding-related death (0.22%). Thus total 30-day death/stroke was 0.66%, and total death/stroke/MI was 0.88%. By 60 months there were 3 contralateral, 1 ipsilateral (device-unrelated), and 2 posterior circulation strokes. Baseline internal carotid artery velocities were 3.72±1.25 and 0.63±0.69 m/s (peak-systolic and end-diastolic). Post-procedural in-stent velocities were normal and remained normal throughout the 60-month follow-up period: 0.78±040 and 0.21±0.10 (1y); 0.75±0.36 0.19±0.09 (2y); 0.75±0,35 and 0.21±0.09 (3y); 0.72±0.27 and 0.20±0.07 (4y); 0.79±0.58 and 0.21±0.11m/s (5y). There were 2 in-stent restenoses by 1y (including 1 that occurred with de novo neck radiotherapy) and 1 other by 2y (total 2y in-stent restenos
doi_str_mv 10.1093/ehjci/ehaa946.2404
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ehjci_ehaa946_2404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjci/ehaa946.2404</oup_id><sourcerecordid>10.1093/ehjci/ehaa946.2404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1254-bc10c121d4822ea17a81ea9ed6058f93609a7141725e5e985bd8c87d0bf0632b3</originalsourceid><addsrcrecordid>eNqNkFFOAjEQhhujiYhewKe5QLEt2-6ubwQRSTAao4lvm9KdlSK7Je0uES_idS3CAXyZfzIz_5_MR8g1ZwPO8uENLlfGxqp1nqiBSFhyQnpcCkFzlchT0mM8l1Sp7P2cXISwYoxliqse-Zm75oO26GtwXWtcjQFcBe0SobbGuwZbatwWPZYQWmxaCLuoNfh4bhuELiBUzoPR3rW2BI_boE231t5-69a6BmwTnd59ImziMkbE4S08j15Gd7PpI518xdgSJOxQe8CtLbExeEnOKr0OeHXUPnm7n7yOH-j8aTobj-bUcCETujCcxY6XSSYEap7qjKPOsVRMZlU-VCzXKU94KiRKzDO5KDOTpSVbVEwNxWLYJ-KQG38NwWNVbLyttd8VnBV7tMUf2uKIttijjSZ6MLlu85_7X0TDgRc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term outcomes of the micronet-covered stent system routine use for carotid revsacularization in stroke prevention: PARADIGM-Extend 5 year evidence</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Mazurek, A ; Borratynska, A ; Tomaszewski, T ; Lesniak-Sobelga, A ; Wilkolek, P ; Gancarczyk, U ; Brozda, M ; Sobieraj, E ; Sikorska, M ; Czyz, L ; Urbanczyk, M ; Trystula, M ; Drazkiewicz, T ; Podolec, P ; Musialek, P</creator><creatorcontrib>Mazurek, A ; Borratynska, A ; Tomaszewski, T ; Lesniak-Sobelga, A ; Wilkolek, P ; Gancarczyk, U ; Brozda, M ; Sobieraj, E ; Sikorska, M ; Czyz, L ; Urbanczyk, M ; Trystula, M ; Drazkiewicz, T ; Podolec, P ; Musialek, P</creatorcontrib><description>Abstract Background Diffusion-weighted magnetic resonance imaging indicates that micronet-covered embolic prevention stent system effectively minimizes peri-procedural and prevents lesion-related post-procedural cerebral embolism in carotid artery stenting but long-term clinical evidence is missing. Purpose To provide long-term clinical and duplex ultrasound evaluation of safety and efficacy of the system use in consecutive carotid revascularization patients. Methods PARADIGM-EXTEND is in all-comer, all-referrals-tracked study with no exclusion criteria other than lack of NeuroVascular Team-determined indication. Clinically asymptomatic patients receive revascularization only in case of increased-stroke-risk characteristics. Adverse events are independently adjudicated. Results Currently 451 patients (48–87 years, 59% symptomatic, 127 women) with 490 arteries crossed the first follow-up window of 30 days. There has been 100% micronet-covered embolic prevention stent system use (ie, no other stent type/s used throughout study). Proximal/distal intra-procedural neuroprotection use was 38.3%/61.7%. Large balloon/high-pressure stent optimization was routine, leading to a single-digit (mean 6.9%) residual diameter stenosis. Independent neurologist and duplex evaluation are before and after revascularization (48h and 30 days, then yearly). Peri-procedural death or major ischemic stroke rate was 0%. One event (prior infarct scar asymptomatic extension in prolonged hypotension course) was adjudicated as minor stroke (0.22%), and there was 1 periprocedural MI (type 2, in 2-vessel non-revascularizable CTO; 0.22%). By 30 days there were no further ischaemic strokes (0%) but there was 1 haemorrhagic transformation that led to death (0.22%) and 1 bleeding-related death (0.22%). Thus total 30-day death/stroke was 0.66%, and total death/stroke/MI was 0.88%. By 60 months there were 3 contralateral, 1 ipsilateral (device-unrelated), and 2 posterior circulation strokes. Baseline internal carotid artery velocities were 3.72±1.25 and 0.63±0.69 m/s (peak-systolic and end-diastolic). Post-procedural in-stent velocities were normal and remained normal throughout the 60-month follow-up period: 0.78±040 and 0.21±0.10 (1y); 0.75±0.36 0.19±0.09 (2y); 0.75±0,35 and 0.21±0.09 (3y); 0.72±0.27 and 0.20±0.07 (4y); 0.79±0.58 and 0.21±0.11m/s (5y). There were 2 in-stent restenoses by 1y (including 1 that occurred with de novo neck radiotherapy) and 1 other by 2y (total 2y in-stent restenosis of 1.1%) but no further ones (0% in-stent restenosis at 2–5y). Conclusions PARADIGM-Extend long-term clinical and duplex ultrasound evidence is consistent with normal healing and sustained safety and stroke prevention efficacy of the micronet-covered embolic prevention stent system used routinely, on top of optimized medical therapy, for stroke prevention in symptomatic and increased-stroke-risk asymptomatic subjects with carotid stenosis recommended for revasularization by the NeuroVascular Team. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Jagiellonian University Medical College</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/ehjci/ehaa946.2404</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2020-11, Vol.41 (Supplement_2)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Mazurek, A</creatorcontrib><creatorcontrib>Borratynska, A</creatorcontrib><creatorcontrib>Tomaszewski, T</creatorcontrib><creatorcontrib>Lesniak-Sobelga, A</creatorcontrib><creatorcontrib>Wilkolek, P</creatorcontrib><creatorcontrib>Gancarczyk, U</creatorcontrib><creatorcontrib>Brozda, M</creatorcontrib><creatorcontrib>Sobieraj, E</creatorcontrib><creatorcontrib>Sikorska, M</creatorcontrib><creatorcontrib>Czyz, L</creatorcontrib><creatorcontrib>Urbanczyk, M</creatorcontrib><creatorcontrib>Trystula, M</creatorcontrib><creatorcontrib>Drazkiewicz, T</creatorcontrib><creatorcontrib>Podolec, P</creatorcontrib><creatorcontrib>Musialek, P</creatorcontrib><title>Long-term outcomes of the micronet-covered stent system routine use for carotid revsacularization in stroke prevention: PARADIGM-Extend 5 year evidence</title><title>European heart journal</title><description>Abstract Background Diffusion-weighted magnetic resonance imaging indicates that micronet-covered embolic prevention stent system effectively minimizes peri-procedural and prevents lesion-related post-procedural cerebral embolism in carotid artery stenting but long-term clinical evidence is missing. Purpose To provide long-term clinical and duplex ultrasound evaluation of safety and efficacy of the system use in consecutive carotid revascularization patients. Methods PARADIGM-EXTEND is in all-comer, all-referrals-tracked study with no exclusion criteria other than lack of NeuroVascular Team-determined indication. Clinically asymptomatic patients receive revascularization only in case of increased-stroke-risk characteristics. Adverse events are independently adjudicated. Results Currently 451 patients (48–87 years, 59% symptomatic, 127 women) with 490 arteries crossed the first follow-up window of 30 days. There has been 100% micronet-covered embolic prevention stent system use (ie, no other stent type/s used throughout study). Proximal/distal intra-procedural neuroprotection use was 38.3%/61.7%. Large balloon/high-pressure stent optimization was routine, leading to a single-digit (mean 6.9%) residual diameter stenosis. Independent neurologist and duplex evaluation are before and after revascularization (48h and 30 days, then yearly). Peri-procedural death or major ischemic stroke rate was 0%. One event (prior infarct scar asymptomatic extension in prolonged hypotension course) was adjudicated as minor stroke (0.22%), and there was 1 periprocedural MI (type 2, in 2-vessel non-revascularizable CTO; 0.22%). By 30 days there were no further ischaemic strokes (0%) but there was 1 haemorrhagic transformation that led to death (0.22%) and 1 bleeding-related death (0.22%). Thus total 30-day death/stroke was 0.66%, and total death/stroke/MI was 0.88%. By 60 months there were 3 contralateral, 1 ipsilateral (device-unrelated), and 2 posterior circulation strokes. Baseline internal carotid artery velocities were 3.72±1.25 and 0.63±0.69 m/s (peak-systolic and end-diastolic). Post-procedural in-stent velocities were normal and remained normal throughout the 60-month follow-up period: 0.78±040 and 0.21±0.10 (1y); 0.75±0.36 0.19±0.09 (2y); 0.75±0,35 and 0.21±0.09 (3y); 0.72±0.27 and 0.20±0.07 (4y); 0.79±0.58 and 0.21±0.11m/s (5y). There were 2 in-stent restenoses by 1y (including 1 that occurred with de novo neck radiotherapy) and 1 other by 2y (total 2y in-stent restenosis of 1.1%) but no further ones (0% in-stent restenosis at 2–5y). Conclusions PARADIGM-Extend long-term clinical and duplex ultrasound evidence is consistent with normal healing and sustained safety and stroke prevention efficacy of the micronet-covered embolic prevention stent system used routinely, on top of optimized medical therapy, for stroke prevention in symptomatic and increased-stroke-risk asymptomatic subjects with carotid stenosis recommended for revasularization by the NeuroVascular Team. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Jagiellonian University Medical College</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkFFOAjEQhhujiYhewKe5QLEt2-6ubwQRSTAao4lvm9KdlSK7Je0uES_idS3CAXyZfzIz_5_MR8g1ZwPO8uENLlfGxqp1nqiBSFhyQnpcCkFzlchT0mM8l1Sp7P2cXISwYoxliqse-Zm75oO26GtwXWtcjQFcBe0SobbGuwZbatwWPZYQWmxaCLuoNfh4bhuELiBUzoPR3rW2BI_boE231t5-69a6BmwTnd59ImziMkbE4S08j15Gd7PpI518xdgSJOxQe8CtLbExeEnOKr0OeHXUPnm7n7yOH-j8aTobj-bUcCETujCcxY6XSSYEap7qjKPOsVRMZlU-VCzXKU94KiRKzDO5KDOTpSVbVEwNxWLYJ-KQG38NwWNVbLyttd8VnBV7tMUf2uKIttijjSZ6MLlu85_7X0TDgRc</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Mazurek, A</creator><creator>Borratynska, A</creator><creator>Tomaszewski, T</creator><creator>Lesniak-Sobelga, A</creator><creator>Wilkolek, P</creator><creator>Gancarczyk, U</creator><creator>Brozda, M</creator><creator>Sobieraj, E</creator><creator>Sikorska, M</creator><creator>Czyz, L</creator><creator>Urbanczyk, M</creator><creator>Trystula, M</creator><creator>Drazkiewicz, T</creator><creator>Podolec, P</creator><creator>Musialek, P</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201101</creationdate><title>Long-term outcomes of the micronet-covered stent system routine use for carotid revsacularization in stroke prevention: PARADIGM-Extend 5 year evidence</title><author>Mazurek, A ; Borratynska, A ; Tomaszewski, T ; Lesniak-Sobelga, A ; Wilkolek, P ; Gancarczyk, U ; Brozda, M ; Sobieraj, E ; Sikorska, M ; Czyz, L ; Urbanczyk, M ; Trystula, M ; Drazkiewicz, T ; Podolec, P ; Musialek, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1254-bc10c121d4822ea17a81ea9ed6058f93609a7141725e5e985bd8c87d0bf0632b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazurek, A</creatorcontrib><creatorcontrib>Borratynska, A</creatorcontrib><creatorcontrib>Tomaszewski, T</creatorcontrib><creatorcontrib>Lesniak-Sobelga, A</creatorcontrib><creatorcontrib>Wilkolek, P</creatorcontrib><creatorcontrib>Gancarczyk, U</creatorcontrib><creatorcontrib>Brozda, M</creatorcontrib><creatorcontrib>Sobieraj, E</creatorcontrib><creatorcontrib>Sikorska, M</creatorcontrib><creatorcontrib>Czyz, L</creatorcontrib><creatorcontrib>Urbanczyk, M</creatorcontrib><creatorcontrib>Trystula, M</creatorcontrib><creatorcontrib>Drazkiewicz, T</creatorcontrib><creatorcontrib>Podolec, P</creatorcontrib><creatorcontrib>Musialek, P</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazurek, A</au><au>Borratynska, A</au><au>Tomaszewski, T</au><au>Lesniak-Sobelga, A</au><au>Wilkolek, P</au><au>Gancarczyk, U</au><au>Brozda, M</au><au>Sobieraj, E</au><au>Sikorska, M</au><au>Czyz, L</au><au>Urbanczyk, M</au><au>Trystula, M</au><au>Drazkiewicz, T</au><au>Podolec, P</au><au>Musialek, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcomes of the micronet-covered stent system routine use for carotid revsacularization in stroke prevention: PARADIGM-Extend 5 year evidence</atitle><jtitle>European heart journal</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>41</volume><issue>Supplement_2</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Background Diffusion-weighted magnetic resonance imaging indicates that micronet-covered embolic prevention stent system effectively minimizes peri-procedural and prevents lesion-related post-procedural cerebral embolism in carotid artery stenting but long-term clinical evidence is missing. Purpose To provide long-term clinical and duplex ultrasound evaluation of safety and efficacy of the system use in consecutive carotid revascularization patients. Methods PARADIGM-EXTEND is in all-comer, all-referrals-tracked study with no exclusion criteria other than lack of NeuroVascular Team-determined indication. Clinically asymptomatic patients receive revascularization only in case of increased-stroke-risk characteristics. Adverse events are independently adjudicated. Results Currently 451 patients (48–87 years, 59% symptomatic, 127 women) with 490 arteries crossed the first follow-up window of 30 days. There has been 100% micronet-covered embolic prevention stent system use (ie, no other stent type/s used throughout study). Proximal/distal intra-procedural neuroprotection use was 38.3%/61.7%. Large balloon/high-pressure stent optimization was routine, leading to a single-digit (mean 6.9%) residual diameter stenosis. Independent neurologist and duplex evaluation are before and after revascularization (48h and 30 days, then yearly). Peri-procedural death or major ischemic stroke rate was 0%. One event (prior infarct scar asymptomatic extension in prolonged hypotension course) was adjudicated as minor stroke (0.22%), and there was 1 periprocedural MI (type 2, in 2-vessel non-revascularizable CTO; 0.22%). By 30 days there were no further ischaemic strokes (0%) but there was 1 haemorrhagic transformation that led to death (0.22%) and 1 bleeding-related death (0.22%). Thus total 30-day death/stroke was 0.66%, and total death/stroke/MI was 0.88%. By 60 months there were 3 contralateral, 1 ipsilateral (device-unrelated), and 2 posterior circulation strokes. Baseline internal carotid artery velocities were 3.72±1.25 and 0.63±0.69 m/s (peak-systolic and end-diastolic). Post-procedural in-stent velocities were normal and remained normal throughout the 60-month follow-up period: 0.78±040 and 0.21±0.10 (1y); 0.75±0.36 0.19±0.09 (2y); 0.75±0,35 and 0.21±0.09 (3y); 0.72±0.27 and 0.20±0.07 (4y); 0.79±0.58 and 0.21±0.11m/s (5y). There were 2 in-stent restenoses by 1y (including 1 that occurred with de novo neck radiotherapy) and 1 other by 2y (total 2y in-stent restenosis of 1.1%) but no further ones (0% in-stent restenosis at 2–5y). Conclusions PARADIGM-Extend long-term clinical and duplex ultrasound evidence is consistent with normal healing and sustained safety and stroke prevention efficacy of the micronet-covered embolic prevention stent system used routinely, on top of optimized medical therapy, for stroke prevention in symptomatic and increased-stroke-risk asymptomatic subjects with carotid stenosis recommended for revasularization by the NeuroVascular Team. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Jagiellonian University Medical College</abstract><pub>Oxford University Press</pub><doi>10.1093/ehjci/ehaa946.2404</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2020-11, Vol.41 (Supplement_2)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_ehjci_ehaa946_2404
source Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Long-term outcomes of the micronet-covered stent system routine use for carotid revsacularization in stroke prevention: PARADIGM-Extend 5 year evidence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T14%3A09%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcomes%20of%20the%20micronet-covered%20stent%20system%20routine%20use%20for%20carotid%20revsacularization%20in%20stroke%20prevention:%20PARADIGM-Extend%205%20year%20evidence&rft.jtitle=European%20heart%20journal&rft.au=Mazurek,%20A&rft.date=2020-11-01&rft.volume=41&rft.issue=Supplement_2&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/ehjci/ehaa946.2404&rft_dat=%3Coup_cross%3E10.1093/ehjci/ehaa946.2404%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ehjci/ehaa946.2404&rfr_iscdi=true